Showing 1641-1650 of 5771 results for "".
- Pixium Vision Announces Implantation of First Patient in Italy in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-implantation-of-first-patient-in-italy-in-prima-system-european-pivotal-trial-primavera/2481084/Pixium Vision announced the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD). This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical
- Rayner to Announce Launch of RayPRO+ Digital Health Platform at the ESCRShttps://modernod.com/news/rayner-to-announce-launch-of-raypro-digital-health-platform-at-the-escrs/2481082/Rayner announced the global launch of RayPRO+ at the upcoming ESCRS 2022 congress in Milan. RayPRO is Rayner’s proprietary mobile app and web-based digital platform that proactively collects a blend of patient reported outcomes (PROs) over 3 years. RayPRO+ has the added ability to
- Lensar Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EUhttps://modernod.com/news/lensar-announces-application-for-certification-of-the-ally-adaptive-cataract-treatment-system-in-the-eu/2481069/Lensar announced the application for certification of the ALLY Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent US commercial launch, this is another important step in our effort to bring ALLY to
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema
- Oculis Announces Publication and Presentation of Phase 2 Data Showing Topical OCS-01 Improves Macular Thickness and Visual Acuity in Patients with DMEhttps://modernod.com/news/oculis-announces-publication-and-presentation-of-phase-2-data-showing-topical-ocs-01-improves-macular-thickness-and-visual-acuity-in-patients-with-dme/2481066/Oculis SA announced that the phase 2 DX-211, a randomized, double blinded, multicenter and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with diabetic macular edema (DME) (NCT05343156) has been published in the journal Acta Ophthalmolog
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Bausch + Lomb and Novaliq Announce FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-filing-acceptance-for-investigational-treatment-nov03-perfluorohexyloctane/2481063/Bausch + Lomb and Novaliq announced that the FDA has accepted the new drug application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane). A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs an
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real-World Data at EURETINA Annual Congresshttps://modernod.com/news/alimera-announces-multiple-abstracts-highlighting-iluvien-real-world-data-at-euretina-annual-congress/2481055/Alimera Sciences announced that clinical data for ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022. Audio Na
- Bausch + Lomb Announces Strategic Partnership With Munich Surgical Imaging GmbHhttps://modernod.com/news/bausch-lomb-announces-strategic-partnership-with-munich-surgical-imaging-gmbh-1/2481053/Bausch + Lomb announced its strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state‐of‐the art digital visualization and image‐guided surgical applications. The new MSI platform, dev